A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravitreous Injections of HB002.1M (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Neovascular Age-Related Macular Degeneration
Latest Information Update: 05 Nov 2021
At a glance
- Drugs HB00-2M (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Huabo Biopharm
- 28 Jul 2020 Status changed from recruiting to completed.
- 11 Feb 2020 Planned End Date changed from 15 jun 2020 to 15 Jun 2020.
- 11 Feb 2020 Planned primary completion date changed from 1 Dec 2019 to 15 Mar 2020.